APA (7th ed.) Citation

Younossi, Z. M., Razavi, H., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K., . . . Loomba, R. (2025). Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Alimentary Pharmacology & Therapeutics, 61(9), 1467. https://doi.org/10.1111/apt.70020

Chicago Style (17th ed.) Citation

Younossi, Zobair M., et al. "Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective." Alimentary Pharmacology & Therapeutics 61, no. 9 (2025): 1467. https://doi.org/10.1111/apt.70020.

MLA (9th ed.) Citation

Younossi, Zobair M., et al. "Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective." Alimentary Pharmacology & Therapeutics, vol. 61, no. 9, 2025, p. 1467, https://doi.org/10.1111/apt.70020.